Amylyx shares lost roughly half their value in the past week, as investors reacted to FDA staffers recommending against approval of the company’s lead candidate. The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee sided with agency staffers in recommending against approval by a 4–6 vote on Wednesday . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

The post StockWatch: ALS Setback Hammers Amylyx, Longeveron Doubles on Positive Alzheimer’s Data appeared first on GEN – Genetic Engineering and Biotechnology News.

Source